06.08.2018 – 09:11
Press release - STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG - CEO Claudio Albrecht: "Excellent basis for further strong growth in the biosimilar segment"
- 20180806 Press release - STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG.pdf
PDF - 116 kB
STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG
CEO Claudio Albrecht: "Excellent basis for further strong growth in the biosimilar segment"
Bad Vilbel, August 6, 2018 - After repurchasing the rights to Hedrin® from Sanofi, the rights to APO-go® from Grünenthal and the rights to Ladival from Ladival GmbH & Co KG, STADA Arzneimittel AG is also increasing its presence in the important biosimilar sector. Subject to approval by the antitrust authorities, STADA is acquiring an additional 35.48 percent of the shares from its co-shareholders, which - combined with the shares already held - means that it now has a 51.34 percent stake in BIOCEUTICALS Arzneimittel AG. The parties agreed to maintain confidentiality with regard to the financial conditions of the transaction. BIOCEUTICALS Arzneimittel AG manufactures the active ingredient erythropoietin and markets it particularly by issuing sales licenses to STADAPHARM and other third parties.
The biosimilar epoetin zeta, which is sold by STADAPHARM in Germany with the brand name Silapo®, is approved for the treatment of anemia resulting from chronic kidney failure and in chemotherapy.
CEO Claudio Albrecht is particularly pleased about this transaction, "because it is an excellent fit with STADA's three-pillar strategy, in which biosimilars in the Specialties segment play a key role. This will enormously strengthen our Specialties group and forms an excellent basis for further strong growth in this segment." Albrecht thanks the former co-shareholders who have supported the company for many years. "It is also thanks to them that we are among the leaders in this biosimilar segment in Germany with Silapo®."
Since 2008, STADA has been selling the biosimilar with the active ingredient epoetin zeta in Germany with the brand name Silapo® under a sales license issued by BIOCEUTICALS Arzneimittel AG. This makes STADA one of the first companies in the world to put a biosimilar on the market. Sales of this medication have been rising steadily since it was first launched.
Based on further license agreements with BIOCEUTICALS Arzneimittel AG, the product is sold by companies including the hospital specialist Hospira (Pfizer), which sells it under the brand name RetacritTM in various countries and was recently granted approval for this in the USA. The medication is produced by Norbitec GmbH in Uetersen, which is majority owned by BIOCEUTICALS Arzneimittel AG.
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.
Additional information for journalists: STADA Arzneimittel AG Media Relations Stadastrasse 2-18 61118 Bad Vilbel - Germany Phone.: +49 (0) 6101 603-165 Fax: +49 (0) 6101 603-215 E-Mail: firstname.lastname@example.org Or visit us on the Internet at www.stada.com/press Additional information for capital market participants: STADA Arzneimittel AG Investor & Creditor Relations Stadastrasse 2-18 61118 Bad Vilbel Phone.: +49 (0) 6101 603-113 Fax: +49 (0) 6101 603-215 E-mail: email@example.com Or visit us on the Internet at www.stada.com/investor-relations